Source comparison
Comparison Table: Growth Hormone Secretagogue Compounds
Before selecting a peptide, compare receptor affinity, desensitisation profile, and side-effect burden across compound classes. GHRP-6 5–10× 20–30 min Moderate (3–4 weeks) High (ghrelin pathway) 2–6 weeks Acute GH studies, short-term protocols GHRP-2 6–9× Mode
This comparison does not assign a generated winner or score.
- Before selecting a peptide, compare receptor affinity, desensitisation profile, and side-effect burden across compound classes.
- GHRP-6
- 5–10×
- 20–30 min
- Moderate (3–4 weeks)
- High (ghrelin pathway)
- 2–6 weeks
- Acute GH studies, short-term protocols
- GHRP-2
- 6–9×
- Moderate
- Controlled appetite studies
- Hexarelin
- 8–12×
- 60–90 min
- Rapid (14–21 days)
- Low
- 1–2 weeks
- Maximum GH response, short duration
- Ipamorelin
- 3–5×
- 2 hours
- Minimal (6–8 weeks)
- None
- 4–12 weeks
- Long-term IGF-1 elevation, metabolic studies
- CJC-1295 (DAC)
- 2–4× sustained
- 6–8 days
- Minimal (8–12 weeks)
- 8–16 weeks
- Sustained IGF-1, tissue anabolism studies
- MK 677
- 2–3× sustained
- 24 hours
- Minimal (12+ weeks)
- High
- 8–24 weeks
- Oral administration preference, long-term studies